Details of a Researcher - Nakamura Katsunori

Nakamura Katsunori

写真a

Title	Professor
Researcher Number(JSPS Kakenhi)	20361363

To the head of this page.▲

Current Affiliation Organization 【 display / non-display 】

Duty University of the Ryukyus Hospital Professor

To the head of this page.▲

Graduate School 【 display / non-display 】

1989

-

1994

Hokkaido University Graduate School, Division of Food and Medical Sciences Other Other
1994

-

1996

Hokkaido University Graduate School, Division of Pharmaceutical Sciences Master's Course Other
1996

-

1999

Hokkaido University Graduate School, Division of Pharmaceutical Sciences Doctor's Course Other

To the head of this page.▲

Study abroad experiences 【 display / non-display 】

1999.04

-

2001.03

Vanderbilt University, Postdoctoral fellow

To the head of this page.▲

External Career 【 display / non-display 】

1900.01

　

　

Work supervised by Professor Dr. Fred. P. Guengerich
1998.04

-

1999.03

Japan Society for the Promotion of Science Research Fellow
2001.04

-

2003.03

Gunma University Hospital, Pharmacist
2003

　

　

- Assistant Professor of Department of of Clinical Pharmacology, Gunma University School of
2003

display all >>

To the head of this page.▲

Affiliated academic organizations 【 display / non-display 】

1994.04

-

Now

The Pharmaceutical Society of Japan
1994.04

-

Now

The Japanese Society of Clinical Pharmacology and Therapeutics
1999.04

-

Now

International Society for the Study of Xenobiotics
2001.04

-

Now

Japanese Society of Pharmaceutical Health and Science
2010.04

-

2012.03

The Pharmaceutical Society of Japan

display all >>

To the head of this page.▲

Research Interests 【 display / non-display 】

Drug metabolism,Pharmacogenetics,Personalized medicine

To the head of this page.▲

Research Areas 【 display / non-display 】

Life Science / Clinical pharmacy

To the head of this page.▲

Published Papers 【 display / non-display 】

Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation

Shiohira H, Arakaki S, Uehara W, Uehara H, Yamamoto K, Nakamura K.

J Infect Chemother . 30 ( １ ) 77 - 80 2024 [ Peer Review Accepted ]

Type of publication: Research paper (scientific journal)
- Access this article
  
  DOI
Effects of 5-fluorouracil Co-administration on Blood Pressure in Patients Maintained on Antihypertensives: a Retrospective Case Series.

Tayag JCS, Ishii T, Kokuba S, Hirata T, Shiohira H, Nakamura K

Die Pharmazie ( Die Pharmazie ) 78 ( 5 ) 67 - 75 2023.05 [ Peer Review Accepted ]

Type of publication: Research paper (scientific journal)
- Access this article
  
  DOI
- Search related information
  
  PubMed
Warfarin Drug-Drug Interactions with Amiodarone and Tramadol in a Patient with Paroxysmal Atrial Fibrillation: A Case Report

Higa Marina, Katsuren Eisuke, Tayag Jose Carlos S., Iwabuchi Masashi, Ohya Yusuke, Shiohira Hideo, Nakamura Katsunori

BPB Reports ( 公益社団法人日本薬学会 ) 6 ( 3 ) 98 - 102 2023 [ Peer Review Accepted ]

Type of publication: Research paper (scientific journal)

　View Summary

<p>Amiodarone and tramadol are known to have drug-drug interactions that potentiate the effects of the anticoagulant warfarin. Herein we report a case which suggests increasing prothrombin time-international normalized ratio (PT-INR) and PT-INR/dose ratio due to the concomitant administration of warfarin, amiodarone (a cytochrome P450 2C9 inhibitor) and tramadol (an enhancer of anticoagulant effects of warfarin). A 72-year-old woman underwent emergency surgery following a suspected non-obstructive mesenteric ischemia, and diagnosis was confirmed. After surgery, the patient was given 2 mg/day of WF, and tramadol/acetaminophen, followed by amiodarone. After the concomitant dose of the triple combination, the PT-INR increased to over 7.02 (above the upper limit of the laboratory). The physician consulted the pharmacist for dose adjustment, and the pharmacist recommended a reduction in the dose to 0.5 mg. After restarting warfarin, PT-INR was controlled to 1.66–2.02. However, the PT-INR/dose ratio increased from 1.22 to 3.32–4.04 compared to the initial dose. The results suggest that these enhanced anticoagulant effects may be due to the inhibition of WF metabolism. Although the patient underwent resection of the small intestine, the effects of oral vitamin K1 were observed one day after administration. In conclusion, frequent PT-INR monitoring, and pharmacist intervention such as the assessment and dose adjustment in this report should be beneficial during anticoagulation therapy when multiple concomitant medications with suspected drug-drug interactions are present.</p>
- Access this article
  
  DOI Repository
- Search related information
  
  CiNii Research
High-dose methotrexate therapy for a child with B-cell precursor acute lymphoblastic leukemia and congenital solitary kidney.

Hokama N, Hyakuna N, Hamada S, Shiohira H, Nakanishi K, Nakamura K

Pediatric blood & cancer ( Pediatric Blood and Cancer ) 69 ( 8 ) e29567 2022.08 [ Peer Review Accepted ]

Type of publication: Research paper (scientific journal)
- Access this article
  
  DOI
- Search related information
  
  PubMed
Successive disappearance of summer influenza in the Okinawa prefecture during the severe acute respiratory syndrome coronavirus 2 pandemic.

Sunagawa S, Iha Y, Kinjo T, Nakamura K, Fujita J

Respiratory investigation ( Respiratory Investigation ) 60 ( 1 ) 184 - 186 2022.01 [ Peer Review Accepted ]

Type of publication: Research paper (scientific journal)
- Access this article
  
  DOI
- Search related information
  
  PubMed